Dan Levison is a partner at Morrison Foerster and co-Managing Partner of the Singapore office. He also heads its Litigation Department and leads the firm’s Ethics and Compliance regional practice in Asia. Dan counsels clients regarding compliance matters and conducts internal investigations and compliance reviews across the Asia-Pacific region, where he has over 24 years of experience. His practice has included work in many countries in Southeast Asia and beyond, including Malaysia, Thailand, Indonesia, Vietnam, the Philippines, and Singapore.

Clients say that Dan is “a highly skilled lawyer who specializes in managing large, complex internal investigations” and “very thoughtful and thorough, and extremely focused on giving high-quality advice across a broad range of issues.” Clients rely on his experience with highly sensitive and complex cross‑border matters, which have included fraud and corruption, cartel, and other competition matters, anti-money laundering, economic sanctions and export control, privacy and data security, and regulatory and product safety investigations. In addition, he assists clients with pre‑acquisition and third-party compliance due diligence and developing, reviewing, and implementing compliance policies, procedures, and training programs.

Dan also focuses on complex commercial litigation and arbitration matters, with particular emphasis on the resolution of multi-jurisdictional disputes and has developed particular expertise regarding cross‑border electronic discovery matters. He has counselled clients in a range of matters involving contract disputes, business torts, antitrust, product liability, intellectual property, and other issues. Dan has represented clients in a variety of industries, including electronics and manufacturing, software, consulting and professional services, consumer goods, electronic commerce, chemicals, pharmaceuticals and healthcare, sports and entertainment, transportation, construction and real estate, hospitality, insurance, and banking and financial services, among others. Dan is also a member of the firm’s COVID‑19 Task Force.

Before moving to Singapore, Dan spent more than 12 years in MoFo’s Tokyo office, and clients continue to rely on him for his Japan-related expertise, for which he has been recognized by Chambers Global 2020, 2021, and 2022.

Dan has been listed by Chambers Asia-Pacific every year for the last six years as a top practitioner (Band 1) in his field for Corporate Investigations/Anti-corruption. He is recognized as a leading individual for white-collar crime by Legal 500 Asia-Pacific from 2021 - 2024, and is listed as a litigation star by Benchmark Litigation Asia-Pacific. Dan has also been recommended as a global leader in Investigations in Singapore by Who’s Who Legal/Global Investigations Review every year since 2019.

Dan is also a sought–after speaker and thought leader on anti–corruption, investigations, and compliance‑related topics.

In addition to his practice, Dan serves on the firm’s Board of Directors and on its Diversity Strategy Committee, and plays a leadership role in some of the firm’s global diversity initiatives, notably, as a member of the Board of Directors of the firm’s pro bono client, Lawyers for LGBT & Allies Network, and he has been highly commended by Chambers for an Asia-Pacific Diversity & Inclusion Award 2020.

Representative Experience

• A multinational company in connection with an internal investigation into allegations of bribery in Indonesia.
• A real estate investment trust in relation to a compliance risk assessment concerning a joint venture in India. 
• A U.S.-based company in an investigation into corruption and procurement–related irregularities in India. 
• A global technology company in relation to an investigation into allegations of conflicts of interest and accounting irregularities by local management in Southeast Asia.
• Several Asia-based employees of financial institutions in internal and government corruption and money laundering investigations. 
• U.S.-based medical device manufacturer in investigation into allegations of bribery and fraud in Japan.
• A multinational pharmaceutical company in investigations into allegations of irregularities in the conduct of clinical trials in Japan.
• A U.S.-based company with respect to several Japan Fair Trade Commission investigations.
• Providing a global financial institution with anti-corruption counselling with respect to its global private equity and venture capital investments.
• Conducted pre-investment and pre-acquisition anti-corruption and compliance due diligence for U.S., Europe, and Asia-based multinational companies in numerous transactions across the Asia‑Pacific region and beyond.